Combo conditionally recommended for patients with nonsevere disease at risk for severe disease, seronegative patients with severe infection
Uptake Low for Monoclonal Antibodies for COVID-19
Use peaked in January and declined in early 2021, at the time of the vaccine rollout
Government Buys More Monoclonal Antibody Treatments to Ward Off Shortage
Biden administration has also taken over distributing the therapeutics to help avoid shortages and to ensure equitable distribution
Baricitinib Does Not Cut COVID-19 Progression in Hospitalized Adults
But placebo-controlled trial shows lower all-cause mortality at 28 days and 60 days in patients receiving baricitinib plus standard of care
Stop Use of Ivermectin for COVID-19: AMA, Pharmacist Groups
No form of ivermectin has been approved to treat or prevent COVID-19
Monoclonal Antibody Therapy May Cut COVID-19 Hospitalizations
Lower hospitalization rates seen at 14, 21, 28 days for high-risk patients with mild-to-moderate COVID-19 who received casirivimab-imdevimab
Prescriptions Rise for Veterinary Drug for COVID-19 Patients
Increase in demand for ivermectin has been accompanied by a fivefold increase in calls to poison control centers
Stop Using Ivermectin Veterinary Drug to Treat COVID-19, FDA Urges
No form of ivermectin has been approved to treat or prevent COVID-19, the agency emphasized
Dexamethasone Underused for Adults Hospitalized With COVID-19
Dexamethasone and remdesivir use have gradually increased during the pandemic; hydroxychloroquine use peaked in March 2020
AAP: Consider Palivizumab for Atypical Interseasonal RSV
AAP strongly supports consideration of palivizumab for patients who would be candidates per current eligibility recommendations